Institutional Investors Hate on Allergan Inc Crashed

Allergan plc (NYSE:AGN) Logo

Sentiment for Allergan Inc (NYSE:AGN)

Allergan Inc (NYSE:AGN) institutional sentiment decreased to 0 in 2019 Q2. Its down -2.00, from 2 in 2019Q1. The ratio has worsened, as 0 investment managers started new and increased positions, while 4 sold and reduced their equity positions in Allergan Inc. The investment managers in our partner’s database reported: 20,340 shares, down from 25,607 shares in 2019Q1. Also, the number of investment managers holding Allergan Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 0 New Position: 0.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.50 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

The stock decreased 0.13% or $0.21 during the last trading session, reaching $166.14. About 2.12 million shares traded. Allergan plc (NYSE:AGN) has declined 12.77% since September 13, 2018 and is downtrending. It has underperformed by 12.77% the S&P500.

Analysts await Allergan plc (NYSE:AGN) to report earnings on October, 29. They expect $4.21 earnings per share, down 0.94 % or $0.04 from last year’s $4.25 per share. AGN’s profit will be $1.38 billion for 9.87 P/E if the $4.21 EPS becomes a reality. After $4.38 actual earnings per share reported by Allergan plc for the previous quarter, Wall Street now forecasts -3.88 % negative EPS growth.

Mitchell Mcleod Pugh & Williams Inc holds 0.46% of its portfolio in Allergan plc for 3,982 shares. Callahan Advisors Llc owns 12,774 shares or 0.38% of their US portfolio. Moreover, Cullinan Associates Inc has 0.02% invested in the company for 2,000 shares. The Pennsylvania-based Staley Capital Advisers Inc has invested 0.02% in the stock. Gemmer Asset Management Llc, a California-based fund reported 145 shares.

Allergan plc (NYSE:AGN) Ratings Coverage

Ratings analysis reveals 40% of Allergan’s analysts are positive. Out of 10 Wall Street analysts rating Allergan, 4 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $13300 while the high is $18900. The stock’s average target of $166.50 is 0.22% above today’s ($166.14) share price. AGN was included in 25 notes of analysts from March 20, 2019. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, May 8 report. On Wednesday, March 20 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was maintained by UBS with “Buy” on Thursday, September 12. UBS maintained Allergan plc (NYSE:AGN) rating on Wednesday, April 3. UBS has “Buy” rating and $173 target. UBS maintained the shares of AGN in report on Thursday, May 9 with “Buy” rating. The firm has “Outperform” rating given on Thursday, May 9 by Raymond James. The company was downgraded on Thursday, July 18 by Leerink Swann. The firm has “Hold” rating by Credit Suisse given on Monday, March 25. RBC Capital Markets maintained the stock with “Hold” rating in Monday, March 25 report. The company was maintained on Tuesday, June 25 by Mizuho.

More notable recent Allergan plc (NYSE:AGN) news were published by: which released: “Allergan plc’s (NYSE:AGN) Profit Outlook – Yahoo Finance” on June 15, 2019, also with their article: “Consider This Before Buying Allergan plc (NYSE:AGN) For The 2.2% Dividend – Yahoo Finance” published on May 16, 2019, published: “Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) – PRNewswire” on August 22, 2019. More interesting news about Allergan plc (NYSE:AGN) were released by: and their article: “Is Allergan plc (AGN) A Good Stock To Buy ? – Yahoo Finance” published on June 10, 2019 as well as‘s news article titled: “Allergan (AGN) Receives FDA Approval of Juvederm VOLUMA XC For Mid-Face Injection Via Cannula –” with publication date: September 03, 2019.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.